<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602807</url>
  </required_header>
  <id_info>
    <org_study_id>ESWT-tx</org_study_id>
    <nct_id>NCT03602807</nct_id>
  </id_info>
  <brief_title>Safety and Effect of Low-Energy Extracorporeal Shockwave Therapy (ESWT) on the Renal Allograft in Transplant Recipients.</brief_title>
  <official_title>Safety and Effect of Low-Energy Extracorporeal Shockwave Therapy (ESWT) on the Renal Allograft in Transplant Recipients - a Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate the safety and potential effect of Low-energy Shockwave Therapy
      (ESWT) on the transplanted kidney. The treatment consist of ESWT two times a week for three
      weeks, six treatments in total.

      The hypothesis is that ESWT with improve the renal function, by reducing proteinuria (in a
      24-hour urine collection test) and improving renal clearance of 51Cr-EDTA.

      The safety of ESWT on the renal allograft will be assessed during and after treatments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in renal clearance (GFR)</measure>
    <time_frame>At baseline and 3 months after treatment</time_frame>
    <description>Comparing GFR before and 3 months after treatment sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in albumin/creatine ratio in 24hour urine sample</measure>
    <time_frame>At baseline, 1 month after treatment and 3 months after treatment</time_frame>
    <description>Comparing the results from a sample of 24-hour urine sample before, 1 month after and 3 months after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidens of treatment-related adverse events</measure>
    <time_frame>up to 4 months</time_frame>
    <description>The participants answer questions about side-effects before and after each treatment session, at 1 month followup and 3 month followup.
After 1 month a ultrasound of the kidney will show if there is any bleeding in the graft-tissue after the 6 treatments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Transplant Dysfunction</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporeal Shockwave Therapy</intervention_name>
    <description>2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.
Treatment is performed using the STORZ DUOLITHÂ® SD1 T-TOP &quot;F-SW ultra&quot;</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum 1 year ago since last kidney transplant

          -  P-Creatinin under 300, in the last 3 blood-samples

          -  U-Albumine/creatinine ratio over 100, in the last 3 urine-samples

        Exclusion Criteria:

          -  Not Danish speaking.

          -  Obstructive uropathy

          -  Suspected autoimmune disease in the kidney graft

          -  Symptomatic urinal tract infection (UTI)

          -  Severe psychiatric disorder

          -  Pregnant or planning on becoming pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronja N Lundrup, BSc.med</last_name>
    <phone>+45 40 76 40 05</phone>
    <email>rolun13@student.sdu.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Lund, Professor, MD</last_name>
    <email>lars.lund@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Region Of Southern Denmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronja N Lundrup, BSc.med</last_name>
      <phone>+45 40 76 40 05</phone>
      <email>rolun13@student.sdu.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Ronja Niemann Lundrup</investigator_full_name>
    <investigator_title>Undergraduate researcher, BSc.med</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

